Cargando…

Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1

Cancer is one of the leading causes of death worldwide, and its incidence and mortality are increasing each year. Improved therapeutic strategies against cancer have progressed, but remain insufficient to invert this trend. Along with several other risk factors, abnormal genetic and epigenetic regul...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashraf, Waseem, Ahmad, Tanveer, Reynoird, Nicolas, Hamiche, Ali, Mély, Yves, Bronner, Christian, Mousli, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459542/
https://www.ncbi.nlm.nih.gov/pubmed/37630248
http://dx.doi.org/10.3390/molecules28165997
_version_ 1785097436434268160
author Ashraf, Waseem
Ahmad, Tanveer
Reynoird, Nicolas
Hamiche, Ali
Mély, Yves
Bronner, Christian
Mousli, Marc
author_facet Ashraf, Waseem
Ahmad, Tanveer
Reynoird, Nicolas
Hamiche, Ali
Mély, Yves
Bronner, Christian
Mousli, Marc
author_sort Ashraf, Waseem
collection PubMed
description Cancer is one of the leading causes of death worldwide, and its incidence and mortality are increasing each year. Improved therapeutic strategies against cancer have progressed, but remain insufficient to invert this trend. Along with several other risk factors, abnormal genetic and epigenetic regulations play a critical role in the initiation of cellular transformation, as well as tumorigenesis. The epigenetic regulator UHRF1 (ubiquitin-like, containing PHD and RING finger domains 1) is a multidomain protein with oncogenic abilities overexpressed in most cancers. Through the coordination of its multiple domains and other epigenetic key players, UHRF1 regulates DNA methylation and histone modifications. This well-coordinated dialogue leads to the silencing of tumor-suppressor genes (TSGs) and facilitates tumor cells’ resistance toward anticancer drugs, ultimately promoting apoptosis escape and uncontrolled proliferation. Several studies have shown that the downregulation of UHRF1 with natural compounds in tumor cells induces the reactivation of various TSGs, inhibits cell growth, and promotes apoptosis. In this review, we discuss the underlying mechanisms and the potential of various natural and synthetic compounds that can inhibit/minimize UHRF1’s oncogenic activities and/or its expression.
format Online
Article
Text
id pubmed-10459542
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104595422023-08-27 Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1 Ashraf, Waseem Ahmad, Tanveer Reynoird, Nicolas Hamiche, Ali Mély, Yves Bronner, Christian Mousli, Marc Molecules Review Cancer is one of the leading causes of death worldwide, and its incidence and mortality are increasing each year. Improved therapeutic strategies against cancer have progressed, but remain insufficient to invert this trend. Along with several other risk factors, abnormal genetic and epigenetic regulations play a critical role in the initiation of cellular transformation, as well as tumorigenesis. The epigenetic regulator UHRF1 (ubiquitin-like, containing PHD and RING finger domains 1) is a multidomain protein with oncogenic abilities overexpressed in most cancers. Through the coordination of its multiple domains and other epigenetic key players, UHRF1 regulates DNA methylation and histone modifications. This well-coordinated dialogue leads to the silencing of tumor-suppressor genes (TSGs) and facilitates tumor cells’ resistance toward anticancer drugs, ultimately promoting apoptosis escape and uncontrolled proliferation. Several studies have shown that the downregulation of UHRF1 with natural compounds in tumor cells induces the reactivation of various TSGs, inhibits cell growth, and promotes apoptosis. In this review, we discuss the underlying mechanisms and the potential of various natural and synthetic compounds that can inhibit/minimize UHRF1’s oncogenic activities and/or its expression. MDPI 2023-08-10 /pmc/articles/PMC10459542/ /pubmed/37630248 http://dx.doi.org/10.3390/molecules28165997 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ashraf, Waseem
Ahmad, Tanveer
Reynoird, Nicolas
Hamiche, Ali
Mély, Yves
Bronner, Christian
Mousli, Marc
Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1
title Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1
title_full Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1
title_fullStr Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1
title_full_unstemmed Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1
title_short Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1
title_sort natural and synthetic anticancer epidrugs targeting the epigenetic integrator uhrf1
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459542/
https://www.ncbi.nlm.nih.gov/pubmed/37630248
http://dx.doi.org/10.3390/molecules28165997
work_keys_str_mv AT ashrafwaseem naturalandsyntheticanticancerepidrugstargetingtheepigeneticintegratoruhrf1
AT ahmadtanveer naturalandsyntheticanticancerepidrugstargetingtheepigeneticintegratoruhrf1
AT reynoirdnicolas naturalandsyntheticanticancerepidrugstargetingtheepigeneticintegratoruhrf1
AT hamicheali naturalandsyntheticanticancerepidrugstargetingtheepigeneticintegratoruhrf1
AT melyyves naturalandsyntheticanticancerepidrugstargetingtheepigeneticintegratoruhrf1
AT bronnerchristian naturalandsyntheticanticancerepidrugstargetingtheepigeneticintegratoruhrf1
AT mouslimarc naturalandsyntheticanticancerepidrugstargetingtheepigeneticintegratoruhrf1